 | • レポートコード：GIR-23F3731 • 出版社/出版日：GlobalInfoResearch / 2023年2月 • レポート形態：英文、PDF、74ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Acute Intermittent Porphyria Drugs Market」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社（香港）の最新の調査によると、世界の急性間欠性ポルフィリン症治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 急性間欠性ポルフィリン症治療薬市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次を対象にします。 ・350mg、313mg アプリケーション別セグメントは次のように区分されます。 ・病院、薬局 世界の急性間欠性ポルフィリン症治療薬市場の主要なマーケットプレーヤーは以下のとおりです。 ・Abbott 地域別セグメントは次の地域・国を対象にします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） ***** 目次(一部) ***** ・市場概要 - 急性間欠性ポルフィリン症治療薬の概要 - タイプ別分析（2017年vs2021年vs2028年）：350mg、313mg - アプリケーション別分析（2017年vs2021年vs2028年）：病院、薬局 - 世界の急性間欠性ポルフィリン症治療薬市場規模・予測 - 世界の急性間欠性ポルフィリン症治療薬生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Abbott ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：350mg、313mg ・アプリケーション別分析2017年-2028年：病院、薬局 ・急性間欠性ポルフィリン症治療薬の北米市場分析 - 急性間欠性ポルフィリン症治療薬の北米市場：タイプ別市場規模2017年-2028年 - 急性間欠性ポルフィリン症治療薬の北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・急性間欠性ポルフィリン症治療薬のヨーロッパ市場分析 - ：急性間欠性ポルフィリン症治療薬のヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：急性間欠性ポルフィリン症治療薬のヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・急性間欠性ポルフィリン症治療薬のアジア太平洋市場分析 - 急性間欠性ポルフィリン症治療薬のアジア太平洋市場：タイプ別市場規模2017年-2028年 - 急性間欠性ポルフィリン症治療薬のアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・急性間欠性ポルフィリン症治療薬の南米市場分析 - 急性間欠性ポルフィリン症治療薬の南米市場：タイプ別市場規模2017年-2028年 - 急性間欠性ポルフィリン症治療薬の南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・急性間欠性ポルフィリン症治療薬の中東・アフリカ市場分析 - 急性間欠性ポルフィリン症治療薬の中東・アフリカ市場：タイプ別市場規模2017年-2028年 - 急性間欠性ポルフィリン症治療薬の中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Acute Intermittent Porphyria Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Acute Intermittent Porphyria Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Acute Intermittent Porphyria Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 350mg segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Acute Intermittent Porphyria Drugs include Abbott, , , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Acute Intermittent Porphyria Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
350mg
313mg
Market segment by Application can be divided into
Hospital
Pharmacy
The key market players for global Acute Intermittent Porphyria Drugs market are listed below:
Abbott
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Acute Intermittent Porphyria Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Acute Intermittent Porphyria Drugs, with price, sales, revenue and global market share of Acute Intermittent Porphyria Drugs from 2019 to 2022.
Chapter 3, the Acute Intermittent Porphyria Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Acute Intermittent Porphyria Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Acute Intermittent Porphyria Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Acute Intermittent Porphyria Drugs.
Chapter 13, 14, and 15, to describe Acute Intermittent Porphyria Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Acute Intermittent Porphyria Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Acute Intermittent Porphyria Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 350mg
1.2.3 313mg
1.3 Market Analysis by Application
1.3.1 Overview: Global Acute Intermittent Porphyria Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Acute Intermittent Porphyria Drugs Market Size & Forecast
1.4.1 Global Acute Intermittent Porphyria Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Acute Intermittent Porphyria Drugs Sales in Volume (2017-2028)
1.4.3 Global Acute Intermittent Porphyria Drugs Price (2017-2028)
1.5 Global Acute Intermittent Porphyria Drugs Production Capacity Analysis
1.5.1 Global Acute Intermittent Porphyria Drugs Total Production Capacity (2017-2028)
1.5.2 Global Acute Intermittent Porphyria Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Acute Intermittent Porphyria Drugs Market Drivers
1.6.2 Acute Intermittent Porphyria Drugs Market Restraints
1.6.3 Acute Intermittent Porphyria Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Abbott
2.1.1 Abbott Details
2.1.2 Abbott Major Business
2.1.3 Abbott Acute Intermittent Porphyria Drugs Product and Services
2.1.4 Abbott Acute Intermittent Porphyria Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Acute Intermittent Porphyria Drugs Breakdown Data by Manufacturer
3.1 Global Acute Intermittent Porphyria Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Acute Intermittent Porphyria Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Acute Intermittent Porphyria Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Acute Intermittent Porphyria Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Acute Intermittent Porphyria Drugs Manufacturer Market Share in 2021
3.5 Global Acute Intermittent Porphyria Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Acute Intermittent Porphyria Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Acute Intermittent Porphyria Drugs Market Size by Region
4.1.1 Global Acute Intermittent Porphyria Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Acute Intermittent Porphyria Drugs Revenue by Region (2017-2028)
4.2 North America Acute Intermittent Porphyria Drugs Revenue (2017-2028)
4.3 Europe Acute Intermittent Porphyria Drugs Revenue (2017-2028)
4.4 Asia-Pacific Acute Intermittent Porphyria Drugs Revenue (2017-2028)
4.5 South America Acute Intermittent Porphyria Drugs Revenue (2017-2028)
4.6 Middle East and Africa Acute Intermittent Porphyria Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Acute Intermittent Porphyria Drugs Sales in Volume by Type (2017-2028)
5.2 Global Acute Intermittent Porphyria Drugs Revenue by Type (2017-2028)
5.3 Global Acute Intermittent Porphyria Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Acute Intermittent Porphyria Drugs Sales in Volume by Application (2017-2028)
6.2 Global Acute Intermittent Porphyria Drugs Revenue by Application (2017-2028)
6.3 Global Acute Intermittent Porphyria Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Acute Intermittent Porphyria Drugs Sales by Type (2017-2028)
7.2 North America Acute Intermittent Porphyria Drugs Sales by Application (2017-2028)
7.3 North America Acute Intermittent Porphyria Drugs Market Size by Country
7.3.1 North America Acute Intermittent Porphyria Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Acute Intermittent Porphyria Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Acute Intermittent Porphyria Drugs Sales by Type (2017-2028)
8.2 Europe Acute Intermittent Porphyria Drugs Sales by Application (2017-2028)
8.3 Europe Acute Intermittent Porphyria Drugs Market Size by Country
8.3.1 Europe Acute Intermittent Porphyria Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Acute Intermittent Porphyria Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Acute Intermittent Porphyria Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Acute Intermittent Porphyria Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Acute Intermittent Porphyria Drugs Market Size by Region
9.3.1 Asia-Pacific Acute Intermittent Porphyria Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Acute Intermittent Porphyria Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Acute Intermittent Porphyria Drugs Sales by Type (2017-2028)
10.2 South America Acute Intermittent Porphyria Drugs Sales by Application (2017-2028)
10.3 South America Acute Intermittent Porphyria Drugs Market Size by Country
10.3.1 South America Acute Intermittent Porphyria Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Acute Intermittent Porphyria Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Acute Intermittent Porphyria Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Acute Intermittent Porphyria Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Acute Intermittent Porphyria Drugs Market Size by Country
11.3.1 Middle East & Africa Acute Intermittent Porphyria Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Acute Intermittent Porphyria Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Acute Intermittent Porphyria Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Acute Intermittent Porphyria Drugs
12.3 Acute Intermittent Porphyria Drugs Production Process
12.4 Acute Intermittent Porphyria Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Acute Intermittent Porphyria Drugs Typical Distributors
13.3 Acute Intermittent Porphyria Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global Acute Intermittent Porphyria Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Acute Intermittent Porphyria Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Abbott Basic Information, Manufacturing Base and Competitors
Table 4. Abbott Major Business
Table 5. Abbott Acute Intermittent Porphyria Drugs Product and Services
Table 6. Abbott Acute Intermittent Porphyria Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Global Acute Intermittent Porphyria Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 8. Global Acute Intermittent Porphyria Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 9. Market Position of Manufacturers in Acute Intermittent Porphyria Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 10. Global Acute Intermittent Porphyria Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 11. Head Office and Acute Intermittent Porphyria Drugs Production Site of Key Manufacturer
Table 12. Acute Intermittent Porphyria Drugs New Entrant and Capacity Expansion Plans
Table 13. Acute Intermittent Porphyria Drugs Mergers & Acquisitions in the Past Five Years
Table 14. Global Acute Intermittent Porphyria Drugs Sales by Region (2017-2022) & (K Units)
Table 15. Global Acute Intermittent Porphyria Drugs Sales by Region (2023-2028) & (K Units)
Table 16. Global Acute Intermittent Porphyria Drugs Revenue by Region (2017-2022) & (USD Million)
Table 17. Global Acute Intermittent Porphyria Drugs Revenue by Region (2023-2028) & (USD Million)
Table 18. Global Acute Intermittent Porphyria Drugs Sales by Type (2017-2022) & (K Units)
Table 19. Global Acute Intermittent Porphyria Drugs Sales by Type (2023-2028) & (K Units)
Table 20. Global Acute Intermittent Porphyria Drugs Revenue by Type (2017-2022) & (USD Million)
Table 21. Global Acute Intermittent Porphyria Drugs Revenue by Type (2023-2028) & (USD Million)
Table 22. Global Acute Intermittent Porphyria Drugs Price by Type (2017-2022) & (USD/Unit)
Table 23. Global Acute Intermittent Porphyria Drugs Price by Type (2023-2028) & (USD/Unit)
Table 24. Global Acute Intermittent Porphyria Drugs Sales by Application (2017-2022) & (K Units)
Table 25. Global Acute Intermittent Porphyria Drugs Sales by Application (2023-2028) & (K Units)
Table 26. Global Acute Intermittent Porphyria Drugs Revenue by Application (2017-2022) & (USD Million)
Table 27. Global Acute Intermittent Porphyria Drugs Revenue by Application (2023-2028) & (USD Million)
Table 28. Global Acute Intermittent Porphyria Drugs Price by Application (2017-2022) & (USD/Unit)
Table 29. Global Acute Intermittent Porphyria Drugs Price by Application (2023-2028) & (USD/Unit)
Table 30. North America Acute Intermittent Porphyria Drugs Sales by Country (2017-2022) & (K Units)
Table 31. North America Acute Intermittent Porphyria Drugs Sales by Country (2023-2028) & (K Units)
Table 32. North America Acute Intermittent Porphyria Drugs Revenue by Country (2017-2022) & (USD Million)
Table 33. North America Acute Intermittent Porphyria Drugs Revenue by Country (2023-2028) & (USD Million)
Table 34. North America Acute Intermittent Porphyria Drugs Sales by Type (2017-2022) & (K Units)
Table 35. North America Acute Intermittent Porphyria Drugs Sales by Type (2023-2028) & (K Units)
Table 36. North America Acute Intermittent Porphyria Drugs Sales by Application (2017-2022) & (K Units)
Table 37. North America Acute Intermittent Porphyria Drugs Sales by Application (2023-2028) & (K Units)
Table 38. Europe Acute Intermittent Porphyria Drugs Sales by Country (2017-2022) & (K Units)
Table 39. Europe Acute Intermittent Porphyria Drugs Sales by Country (2023-2028) & (K Units)
Table 40. Europe Acute Intermittent Porphyria Drugs Revenue by Country (2017-2022) & (USD Million)
Table 41. Europe Acute Intermittent Porphyria Drugs Revenue by Country (2023-2028) & (USD Million)
Table 42. Europe Acute Intermittent Porphyria Drugs Sales by Type (2017-2022) & (K Units)
Table 43. Europe Acute Intermittent Porphyria Drugs Sales by Type (2023-2028) & (K Units)
Table 44. Europe Acute Intermittent Porphyria Drugs Sales by Application (2017-2022) & (K Units)
Table 45. Europe Acute Intermittent Porphyria Drugs Sales by Application (2023-2028) & (K Units)
Table 46. Asia-Pacific Acute Intermittent Porphyria Drugs Sales by Region (2017-2022) & (K Units)
Table 47. Asia-Pacific Acute Intermittent Porphyria Drugs Sales by Region (2023-2028) & (K Units)
Table 48. Asia-Pacific Acute Intermittent Porphyria Drugs Revenue by Region (2017-2022) & (USD Million)
Table 49. Asia-Pacific Acute Intermittent Porphyria Drugs Revenue by Region (2023-2028) & (USD Million)
Table 50. Asia-Pacific Acute Intermittent Porphyria Drugs Sales by Type (2017-2022) & (K Units)
Table 51. Asia-Pacific Acute Intermittent Porphyria Drugs Sales by Type (2023-2028) & (K Units)
Table 52. Asia-Pacific Acute Intermittent Porphyria Drugs Sales by Application (2017-2022) & (K Units)
Table 53. Asia-Pacific Acute Intermittent Porphyria Drugs Sales by Application (2023-2028) & (K Units)
Table 54. South America Acute Intermittent Porphyria Drugs Sales by Country (2017-2022) & (K Units)
Table 55. South America Acute Intermittent Porphyria Drugs Sales by Country (2023-2028) & (K Units)
Table 56. South America Acute Intermittent Porphyria Drugs Revenue by Country (2017-2022) & (USD Million)
Table 57. South America Acute Intermittent Porphyria Drugs Revenue by Country (2023-2028) & (USD Million)
Table 58. South America Acute Intermittent Porphyria Drugs Sales by Type (2017-2022) & (K Units)
Table 59. South America Acute Intermittent Porphyria Drugs Sales by Type (2023-2028) & (K Units)
Table 60. South America Acute Intermittent Porphyria Drugs Sales by Application (2017-2022) & (K Units)
Table 61. South America Acute Intermittent Porphyria Drugs Sales by Application (2023-2028) & (K Units)
Table 62. Middle East & Africa Acute Intermittent Porphyria Drugs Sales by Region (2017-2022) & (K Units)
Table 63. Middle East & Africa Acute Intermittent Porphyria Drugs Sales by Region (2023-2028) & (K Units)
Table 64. Middle East & Africa Acute Intermittent Porphyria Drugs Revenue by Region (2017-2022) & (USD Million)
Table 65. Middle East & Africa Acute Intermittent Porphyria Drugs Revenue by Region (2023-2028) & (USD Million)
Table 66. Middle East & Africa Acute Intermittent Porphyria Drugs Sales by Type (2017-2022) & (K Units)
Table 67. Middle East & Africa Acute Intermittent Porphyria Drugs Sales by Type (2023-2028) & (K Units)
Table 68. Middle East & Africa Acute Intermittent Porphyria Drugs Sales by Application (2017-2022) & (K Units)
Table 69. Middle East & Africa Acute Intermittent Porphyria Drugs Sales by Application (2023-2028) & (K Units)
Table 70. Acute Intermittent Porphyria Drugs Raw Material
Table 71. Key Manufacturers of Acute Intermittent Porphyria Drugs Raw Materials
Table 72. Direct Channel Pros & Cons
Table 73. Indirect Channel Pros & Cons
Table 74. Acute Intermittent Porphyria Drugs Typical Distributors
Table 75. Acute Intermittent Porphyria Drugs Typical Customers
List of Figures
Figure 1. Acute Intermittent Porphyria Drugs Picture
Figure 2. Global Acute Intermittent Porphyria Drugs Revenue Market Share by Type in 2021
Figure 3. 350mg
Figure 4. 313mg
Figure 5. Global Acute Intermittent Porphyria Drugs Revenue Market Share by Application in 2021
Figure 6. Hospital
Figure 7. Pharmacy
Figure 8. Global Acute Intermittent Porphyria Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Acute Intermittent Porphyria Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Acute Intermittent Porphyria Drugs Sales (2017-2028) & (K Units)
Figure 11. Global Acute Intermittent Porphyria Drugs Price (2017-2028) & (USD/Unit)
Figure 12. Global Acute Intermittent Porphyria Drugs Production Capacity (2017-2028) & (K Units)
Figure 13. Global Acute Intermittent Porphyria Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Acute Intermittent Porphyria Drugs Market Drivers
Figure 15. Acute Intermittent Porphyria Drugs Market Restraints
Figure 16. Acute Intermittent Porphyria Drugs Market Trends
Figure 17. Global Acute Intermittent Porphyria Drugs Sales Market Share by Manufacturer in 2021
Figure 18. Global Acute Intermittent Porphyria Drugs Revenue Market Share by Manufacturer in 2021
Figure 19. Acute Intermittent Porphyria Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Acute Intermittent Porphyria Drugs Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Acute Intermittent Porphyria Drugs Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Acute Intermittent Porphyria Drugs Sales Market Share by Region (2017-2028)
Figure 23. Global Acute Intermittent Porphyria Drugs Revenue Market Share by Region (2017-2028)
Figure 24. North America Acute Intermittent Porphyria Drugs Revenue (2017-2028) & (USD Million)
Figure 25. Europe Acute Intermittent Porphyria Drugs Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Acute Intermittent Porphyria Drugs Revenue (2017-2028) & (USD Million)
Figure 27. South America Acute Intermittent Porphyria Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Acute Intermittent Porphyria Drugs Revenue (2017-2028) & (USD Million)
Figure 29. Global Acute Intermittent Porphyria Drugs Sales Market Share by Type (2017-2028)
Figure 30. Global Acute Intermittent Porphyria Drugs Revenue Market Share by Type (2017-2028)
Figure 31. Global Acute Intermittent Porphyria Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 32. Global Acute Intermittent Porphyria Drugs Sales Market Share by Application (2017-2028)
Figure 33. Global Acute Intermittent Porphyria Drugs Revenue Market Share by Application (2017-2028)
Figure 34. Global Acute Intermittent Porphyria Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 35. North America Acute Intermittent Porphyria Drugs Sales Market Share by Type (2017-2028)
Figure 36. North America Acute Intermittent Porphyria Drugs Sales Market Share by Application (2017-2028)
Figure 37. North America Acute Intermittent Porphyria Drugs Sales Market Share by Country (2017-2028)
Figure 38. North America Acute Intermittent Porphyria Drugs Revenue Market Share by Country (2017-2028)
Figure 39. United States Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Acute Intermittent Porphyria Drugs Sales Market Share by Type (2017-2028)
Figure 43. Europe Acute Intermittent Porphyria Drugs Sales Market Share by Application (2017-2028)
Figure 44. Europe Acute Intermittent Porphyria Drugs Sales Market Share by Country (2017-2028)
Figure 45. Europe Acute Intermittent Porphyria Drugs Revenue Market Share by Country (2017-2028)
Figure 46. Germany Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Acute Intermittent Porphyria Drugs Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Acute Intermittent Porphyria Drugs Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Acute Intermittent Porphyria Drugs Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Acute Intermittent Porphyria Drugs Revenue Market Share by Region (2017-2028)
Figure 55. China Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Acute Intermittent Porphyria Drugs Sales Market Share by Type (2017-2028)
Figure 62. South America Acute Intermittent Porphyria Drugs Sales Market Share by Application (2017-2028)
Figure 63. South America Acute Intermittent Porphyria Drugs Sales Market Share by Country (2017-2028)
Figure 64. South America Acute Intermittent Porphyria Drugs Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Acute Intermittent Porphyria Drugs Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Acute Intermittent Porphyria Drugs Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Acute Intermittent Porphyria Drugs Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Acute Intermittent Porphyria Drugs Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Acute Intermittent Porphyria Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Acute Intermittent Porphyria Drugs in 2021
Figure 76. Manufacturing Process Analysis of Acute Intermittent Porphyria Drugs
Figure 77. Acute Intermittent Porphyria Drugs Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source